AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LISATA THERAPEUTICS, INC. Director's Dealing 2021

Jan 12, 2021

34931_dirs_2021-01-12_a87fcee0-3a3f-4b9a-8a9c-3d60faa071c9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CALADRIUS BIOSCIENCES, INC. (CLBS)
CIK: 0000320017
Period of Report: 2021-01-11

Reporting Person: KLOSK STEVEN M (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-11	Common Stock	A	37735	—	Acquired	85960	Direct

Footnotes

F1: Represents 37,735 restricted stock units granted under the Issuer's 2018 Equity Incentive Compensation Plan which will vest on January 11, 2022.

F2: Includes 56,027 unvested restricted stock units.